688278.SS Overview

Company Profile

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

Related stocks

2162.HK

2162.HK • China

78.3 HKD

2.94B USD 1Y +9.9%

688266.SS

688266.SS • China

SUZHOU ZELGEN BIOPHARMACEUTICAL

104.25 CNY

4.13B USD 1Y -2.2%

301301.SZ

301301.SZ • China

8.22 CNY

2.75B USD 1Y -24.9%

9606.HK

9606.HK • China

182.7 HKD

2.13B USD 1Y -42.1%

2315.HK

2315.HK • China

69.2 HKD

3.91B USD 1Y +170.7%

300255.SZ

300255.SZ • China

CHANGSHAN PHARMA

22.15 CNY

3.05B USD 1Y -55.1%

600161.SS

600161.SS • China

BEIJING TIANTAN BIOLOGICAL PROD

12.73 CNY

3.77B USD 1Y -34%

688578.SS

688578.SS • China

SHANGHAI ALLIST PHARMACEUTICALS

82.5 CNY

5.56B USD 1Y -23%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Website

https://www.amoytop.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

43.9% p.a.

Max Drawdown (5Y)

-45.3%

Sharpe Ratio (5Y)

0.26

Beta Factor

-0.14

Size Class

Large Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.

🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (43.9% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -45.3% in the extended horizon.